Terms: = Liver cancer AND PSA
380 results:
1. [Exploration and validation of optimal cut-off values for tpsa and fpsa/tpsa screening of prostate cancer at different ages].
Liu XM; Duan HY; Zhang DQ; Chen C; Ji YT; Zhang YM; Feng ZW; Liu Y; Li JJ; Zhang Y; Li CY; Zhang YC; Yang L; Lyu ZY; Song FF; Song FJ; Huang YB
Zhonghua Zhong Liu Za Zhi; 2024 Apr; 46(4):354-364. PubMed ID: 38644271
[No Abstract] [Full Text] [Related]
2. Incidental Detection of Synchronous Benign Hepatic and Splenic Hemangiomas on 18 F-PSMA PET/CT.
Alsaleh MH; Alkhars AS; Albensaad M; Alsharif A
Clin Nucl Med; 2024 Jun; 49(6):e298-e300. PubMed ID: 38537220
[TBL] [Abstract] [Full Text] [Related]
3. Cost-effectiveness analysis of Tislelizumab vs Sorafenib as the first-line treatment of unresectable hepatocellular carcinoma.
Chen Q; Sun Q; Zhang J; Li B; Feng Q; Liu J
PLoS One; 2024; 19(3):e0295090. PubMed ID: 38437209
[TBL] [Abstract] [Full Text] [Related]
4. Early-stage hepatocellular carcinoma screening in patients with chronic hepatitis B in China: a cost-effectiveness analysis.
Nan Y; Garay OU; Lu X; Zhang Y; Xie L; Niu Z; Chen W
J Comp Eff Res; 2024 Apr; 13(4):e230146. PubMed ID: 38415341
[No Abstract] [Full Text] [Related]
5. Pre-treatment
Eisazadeh R; Mirshahvalad SA; Schwieghofer-Zwink G; Hehenwarter L; Rendl G; Gampenrieder S; Greil R; Pirich C; Beheshti M
Mol Imaging Biol; 2024 Apr; 26(2):360-369. PubMed ID: 38360991
[TBL] [Abstract] [Full Text] [Related]
6. Correlation between pre-radical prostatectomy standardized SUVmax ratios detected on 68Ga-PSMA-I&T PET/CT and final histopathology outcomes: an in-depth analysis.
Arıkan MG; Soyluoğlu S; Korkmaz Ü; Taştekin E; Elboğa U; Arda E
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2024; 43(2):100-106. PubMed ID: 38331250
[TBL] [Abstract] [Full Text] [Related]
7. The Impact of Circulating Tumor Cell HOXB13 RNA Detection in Men with Metastatic Castration-Resistant Prostate cancer (mCRPC) Treated with Abiraterone or Enzalutamide.
Halabi S; Guo S; Park JJ; Nanus DM; George DJ; Antonarakis ES; Danila DC; Szmulewitz RZ; McDonnell DP; Norris JD; Lu C; Luo J; Armstrong AJ
Clin Cancer Res; 2024 Mar; 30(6):1152-1159. PubMed ID: 38236581
[TBL] [Abstract] [Full Text] [Related]
8. Aggressive prostatic adenocarcinoma with urothelial-like morphology, with frequent CK7/CK20/HMWK expression and occasional diffuse neuroendocrine features: A clinicopathologic study of 12 cases.
Nguyen NJ; Sherman C; van der Kwast TH; Downes MR
Pathol Res Pract; 2024 Feb; 254():155105. PubMed ID: 38218041
[TBL] [Abstract] [Full Text] [Related]
9. Aberrant expression of GATA3 in metastatic adenocarcinoma of the prostate: an important pitfall.
Lobo J; Tenace NP; Cañete-Portillo S; Carneiro I; Henrique R; Lucianò R; Harik LR; Magi-Galluzzi C
Histopathology; 2024 Feb; 84(3):507-514. PubMed ID: 37965687
[TBL] [Abstract] [Full Text] [Related]
10. A single-center, multi-factor, retrospective study to improve the diagnostic accuracy of primary prostate cancer using [
Lv J; Yu H; Yin H; Shi Y; Shi H
Eur J Nucl Med Mol Imaging; 2024 Feb; 51(3):919-927. PubMed ID: 37940684
[TBL] [Abstract] [Full Text] [Related]
11. Newly developed preclinical models reveal broad-spectrum CDK inhibitors as potent drugs for CRPC exhibiting primary resistance to enzalutamide.
Matsuoka T; Sugiyama A; Miyawaki Y; Hidaka Y; Okuno Y; Sakai H; Tanaka H; Yoshikawa K; Fukui T; Mizuno K; Sumiyoshi T; Goto T; Inoue T; Akamatsu S; Kobayashi T; Nakamura E
Cancer Sci; 2024 Jan; 115(1):283-297. PubMed ID: 37923364
[TBL] [Abstract] [Full Text] [Related]
12. Cost-effectiveness analysis of different screening strategies for helicobacter pylori infection in Iran: A model-based evaluation.
Yousefi M; Rezaei S; Khoshbaten M; Sarmasti M
Helicobacter; 2023 Dec; 28(6):e13027. PubMed ID: 37839058
[TBL] [Abstract] [Full Text] [Related]
13. A Phase 1, Open-label, Dose-Ascending Study to Evaluate the Safety and Tolerability of the Therapeutic Radiopharmaceutical 131I-MIP-1095 for the Treatment of Metastatic Castration-Resistant Prostate cancer.
Laccetti AL; Bodei L; O'Donoghue JA; Weber WA; Morris MJ
Clin Nucl Med; 2023 Nov; 48(11):937-944. PubMed ID: 37812518
[TBL] [Abstract] [Full Text] [Related]
14. Total-body [
Wang Y; Chen Z; Zhu Y; Zhao H; Li L; Huang G; Xue W; Chen R; Liu J
Eur J Nucl Med Mol Imaging; 2023 Nov; 50(13):4096-4106. PubMed ID: 37578502
[TBL] [Abstract] [Full Text] [Related]
15. STAT3/LKB1 controls metastatic prostate cancer by regulating mTORC1/CREB pathway.
Pencik J; Philippe C; Schlederer M; Atas E; Pecoraro M; Grund-Gröschke S; Li WJ; Tracz A; Heidegger I; Lagger S; Trachtová K; Oberhuber M; Heitzer E; Aksoy O; Neubauer HA; Wingelhofer B; Orlova A; Witzeneder N; Dillinger T; Redl E; Greiner G; D'Andrea D; Östman JR; Tangermann S; Hermanova I; Schäfer G; Sternberg F; Pohl EE; Sternberg C; Varady A; Horvath J; Stoiber D; Malcolm TI; Turner SD; Parkes EE; Hantusch B; Egger G; Rose-John S; Poli V; Jain S; Armstrong CWD; Hoermann G; Goffin V; Aberger F; Moriggl R; Carracedo A; McKinney C; Kennedy RD; Klocker H; Speicher MR; Tang DG; Moazzami AA; Heery DM; Hacker M; Kenner L
Mol Cancer; 2023 Aug; 22(1):133. PubMed ID: 37573301
[TBL] [Abstract] [Full Text] [Related]
16. liver Fibrosis Scores and Prostate cancer Risk and Mortality in the Atherosclerosis Risk in Communities Study.
Wang A; Lazo M; Lu J; Couper DJ; Prizment AE; Vitolins MZ; Denmeade SR; Joshu CE; Platz EA
Cancer Prev Res (Phila); 2023 Sep; 16(9):523-530. PubMed ID: 37339266
[TBL] [Abstract] [Full Text] [Related]
17. Towards Developing Novel Prostate cancer Recurrence Suppressors: Acute Toxicity of Pseurotin A, an Orally Active PCSK9 Axis-Targeting Small-Molecule in Swiss Albino Mice.
McGehee OC; Ebrahim HY; Rad AH; Abdelwahed KS; Mudhish EA; King JA; Helal IE; Meyer SA; El Sayed KA
Molecules; 2023 Feb; 28(3):. PubMed ID: 36771126
[TBL] [Abstract] [Full Text] [Related]
18. Extended therapy with [
Mader N; Nguyen Ngoc C; Kirkgöze B; Baumgarten J; Groener D; Klimek K; Happel C; Tselis N; Chun FKH; Grünwald F; Sabet A
Eur J Nucl Med Mol Imaging; 2023 May; 50(6):1811-1821. PubMed ID: 36702927
[TBL] [Abstract] [Full Text] [Related]
19. Drug-eluting Microspheres Compared to Conventional Transarterial Chemoembolization as First Line Treatment for Unresectable Hepatocellular Carcinoma: A Single-center Retrospective Cost-utility Analysis.
Andreozzi G; Lorenzoni V; Bargellini I; Cioni R; Turchetti G
Cardiovasc Intervent Radiol; 2023 Mar; 46(3):319-326. PubMed ID: 36599950
[TBL] [Abstract] [Full Text] [Related]
20. Palmitic acid-modified human serum albumin paclitaxel nanoparticles targeting tumor and macrophages against breast cancer.
Xiang L; Fang C; Feng J; Tan Y; Wu Q; Zhou X; Li J; Gong T
Eur J Pharm Biopharm; 2023 Feb; 183():132-141. PubMed ID: 36592736
[TBL] [Abstract] [Full Text] [Related]
[Next]
